• 1
    Knobel H, Guelar A, Valdecillo G, Aymar I, Diez A, Nogues X. Osteopenia in HIV-infected patients. Is it the disease or is it the treatment? 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, February 2001. [Abstract 629].
  • 2
    Nolan D, Upton R, McKinnon E et al. Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. AIDS 2001; 15: 12751280.
  • 3
    Tebas P, Powderly WG, Claxton S et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 2000; 14: F63F67.
  • 4
    Kofler D. Human immunodeficiency virus-related wasting: malabsorption syndromes. Seminars Oncol 1998; 25 (Suppl. 6): 7075.
  • 5
    Karras A, Lafavrie M, Furco A et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome and nephrogenic diabetes insipidus. Clin Infect Dis 2003; 36: 10701072.
  • 6
    Schaaf B, Aries SP, Kramme E, Steinhoff J, Dalhoff K. Acute renal failure associated with tenofovir treatment in a patient with acquired immunodeficiency syndrome. Clin Infect Dis 2003; 37: e41e43.
  • 7
    Earle KE, Senevirartre T, Shaker J, Shoback D. Fanconi's syndrome in HIV+adults: report of three cases and literature review. J Bone Miner Res 2004; 19: 714721.
  • 8
    Anonymous. Viread (Tenofovir Disoproxil Fumarate) Product Monograph. Foster City, CA, Gilead Sciences, 2001.
  • 9
    Lian LM, Chang YC, Yang CC, Yang JC, Kao KP, Chung MY. Adult Fanconi syndrome with proximal muscle weakness and hypophosphataemic osteomalacia: report of a case. J Formosan Med Assoc 1994; 93: 709714.
  • 10
    Lacy MQ, Gertz MA. Acquired Fanconi's syndrome associated with monoclonal gammopathies. Haematol Oncol Clin North Am 1999; 13: 12731280.
  • 11
    Izzedine M, Launay-Vacher V, Isnard-Bagnis C, Deray G. Drug-induced Fanconi's syndrome. Am J Kidney Dis 2003; 41: 292309.
  • 12
    Luptelli G, Fuscaldo G, Castellucci G, Ciufetti G, Pelli MA, Mannarino E. Severe osteomalacia due to gluten-sensitive enteropathy. Annali Ital Med Intern 1994; 9: 4043.
  • 13
    Reis-Filno-Jarge S, Paiva Maria E, Lopes-Jose M. 47-year-old female with a 7-year history of osteomalacia and hypophosphataemia. Brain Pathol 2004; 14: 111112.
  • 14
    Sapunar J, Roa JC, Moscoso S. Reversion of hypophosphataemia after the excision of a composite haemangioendothelioma in the great toe. Revista Med Chile 2003; 131: 909914.
  • 15
    Edmister KA, Sundaram M. Oncogenic osteomalacia. Seminars Musculoskelet Radiol 2002; 6: 191196.
  • 16
    Quarles LD. FGF23, PHEX and MEPE regulation of phosphate homeostasis and skeletal mineralization. Am J Physiol Endocriol Metab 2003; 285: E1E9.
  • 17
    Brandenburg VM, Ketteler M, Frank RD et al. Bone pain with scintigraphy suggestive of widespread metastases–do not forget phosphate. Nephrol Dial Transplant 2002; 17: 504507.
  • 18
    Bell D, Alele J. Dealing with diabetic nephropathy. Postgrad Med 1999; 105: 8387.
  • 19
    Anonymous. Vioxx Summary of Product Characteristics. ABPI Datasheet Compendium 2004. Epsom, UK, Datapharm Communications, 2004.
  • 20
    Maniglia R, Schwartz A, Moriber-Katz S. Non-steroidal anti-inflammatory nephrotoxicity. Ann Clin Lab Sci 1988; 18: 240252.
  • 21
    Palmer B, Henrich W. Clinical acute renal failure with nonsteroidal antiinflammatory drugs. Seminars Nephrol 1995; 15: 214227.
  • 22
    Eknoyan G. The current status of chronic analgesic and NSAID nephropathy. Curr Opin Nephrol Hypertension 1994; 3: 182188.
  • 23
    Gallant J, Pozniak A, Stszewski S, Lu B, Sayre J, Cheng A. Similar 96-week renal safety profile of Tenofovir DF vs Stavudine when used in combination with lamivudine in ART naïve patients. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, September 2003 [Abstract H-840].
  • 24
    Mauss S, Berger F, Schmutz G. Antiretroviral therapy with tenofovir is associated with mild renal dysfunction. AIDS 2005; 19: 9399.
  • 25
    Harris M, Yip B, Zalunardo N et al. Increases in creatinine during therapy with tenofovir. 2nd International AIDS Society Conference. Paris, France, July 2003 [Oral presentation 55].
  • 26
    Gilead Sciences International Limited. Viread SPC 2004. Viread Product Information. Foster City, CA, USA. Gilead Sciences International Limited, 2004.
  • 27
    Antoniau T, Park-Wyllie LY, Tseng AL. Tenofovir: a nucleotide analog for the management of human immunodeficiency virus infection. Pharmacotherapy 2003; 23: 2943.
  • 28
    Kleinknecht D. Interstitial nephritis, the nephrotic syndrome and chronic renal failure secondary to non-steroidal anti-inflammatory drugs. Seminars Nephrol 1995; 15: 228235.
  • 29
    Ataki S, Ida K, Kanazawa S et al. Flare response seen in therapy for osteomalacia. J Nuclear Med 1998; 39: 2095.
  • 30
    Kaye A. Pituitary adenomas, In: KayeA. ed. Essential Neurosurgery. London, UK, Churchill Livingstone, 1991: 147168.
  • 31
    Taxel P, Kenny A. Differential diagnosis and secondary causes of osteoporosis. Clin Cornerstone 2000; 2: 10983597.
  • 32
    Lawal A, Engelson E, Wang J, Heymsfield S, Kotler D. Effect of oxandrolone upon bone mineral content in malnourished HIV+patients. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, February 2001 [Abstract 636].
  • 33
    Hreshchyshyn M, Hopkins A, Zylstra S, Anbar M. Effects of natural menopause, hysterectomy and oophorectomy on lumbar spine and femoral neck bone densities. Obstetrics Gynaecol 1988; 72: 631638.
  • 34
    Sowers M, Wallace R, Hollis B, Lemke J. Parameters related to 25-OH-D levels in a population-based study of women. Am J Clin Nutr 1986; 43: 621628.
  • 35
    Clurie GPR, Fox PE, Stamp TCB. Four cases of acquired hypophosphataemic (oncogenic) osteomalacia. Problems of diagnosis, treatment and long term management. Rheumatology 2000; 39: 14151421.